Lung cancer is the leading cause of cancer death worldwide. Despite significant advances in research and therapy, a dismal 5-year survival rate of only 10–20% urges the development of reliable preclinical models and effective therapeutic tools. Lung cancer is characterized by a high degree of heterogeneity in its histology, a genomic landscape, and response to therapies that has been traditionally difficult to reproduce in preclinical models. However, the advent of three-dimensional culture technologies has opened new perspectives to recapitulate in vitro individualized tumor features and to anticipate treatment efficacy. The generation of lung cancer organoids (LCOs) has encountered greater challenges as compared to organoids derived from other tumors. In the last two years, many efforts have been dedicated to optimizing LCO-based platforms, resulting in improved rates of LCO production, purity, culture timing, and long-term expansion. However, due to the complexity of lung cancer, further advances are required in order to meet clinical needs. Here, we discuss the evolution of LCO technology and the use of LCOs in basic and translational lung cancer research. Although the field of LCOs is still in its infancy, its prospective development will likely lead to new strategies for drug testing and biomarker identification, thus allowing a more personalised therapeutic approach for lung cancer patients.

Lung Cancer Organoids. The Rough Path to Personalized Medicine / Rossi, Rachele; Laura De Angelis, Maria; Xhelili, Eljona; Sette, Giovanni; Eramo, Adriana; de maria marchiano, Ruggero; CESTA INCANI, Ursula; Francescangeli, Federica; Zeuner, Ann. - In: CANCERS. - ISSN 2072-6694. - 14:15(2022), pp. 1-22. [10.3390/cancers14153703]

Lung Cancer Organoids. The Rough Path to Personalized Medicine

Rachele Rossi;Eljona Xhelili;Giovanni Sette;Adriana Eramo;Ruggero De Maria;Ursula Cesta Incani;Federica Francescangeli;
2022

Abstract

Lung cancer is the leading cause of cancer death worldwide. Despite significant advances in research and therapy, a dismal 5-year survival rate of only 10–20% urges the development of reliable preclinical models and effective therapeutic tools. Lung cancer is characterized by a high degree of heterogeneity in its histology, a genomic landscape, and response to therapies that has been traditionally difficult to reproduce in preclinical models. However, the advent of three-dimensional culture technologies has opened new perspectives to recapitulate in vitro individualized tumor features and to anticipate treatment efficacy. The generation of lung cancer organoids (LCOs) has encountered greater challenges as compared to organoids derived from other tumors. In the last two years, many efforts have been dedicated to optimizing LCO-based platforms, resulting in improved rates of LCO production, purity, culture timing, and long-term expansion. However, due to the complexity of lung cancer, further advances are required in order to meet clinical needs. Here, we discuss the evolution of LCO technology and the use of LCOs in basic and translational lung cancer research. Although the field of LCOs is still in its infancy, its prospective development will likely lead to new strategies for drug testing and biomarker identification, thus allowing a more personalised therapeutic approach for lung cancer patients.
2022
lung cancer; organoids; preclinical models; drug testing; targeted therapy; personalised medicine
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Lung Cancer Organoids. The Rough Path to Personalized Medicine / Rossi, Rachele; Laura De Angelis, Maria; Xhelili, Eljona; Sette, Giovanni; Eramo, Adriana; de maria marchiano, Ruggero; CESTA INCANI, Ursula; Francescangeli, Federica; Zeuner, Ann. - In: CANCERS. - ISSN 2072-6694. - 14:15(2022), pp. 1-22. [10.3390/cancers14153703]
File allegati a questo prodotto
File Dimensione Formato  
Rossi_Lung-Cancer-Organoids_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.58 MB
Formato Adobe PDF
1.58 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1655621
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 10
social impact